Cardiovascular, mortality, and kidney outcomes with GLP-1 receptor agonists in patients with type 2 diabetes: a systematic review and meta-analysis of randomised …
Background GLP-1 receptor agonists reduce major adverse cardiovascular events (MACE)
in patients with type 2 diabetes. However, uncertainty regarding kidney outcomes persists …
in patients with type 2 diabetes. However, uncertainty regarding kidney outcomes persists …
[HTML][HTML] GLP-1 receptor agonists in the treatment of type 2 diabetes–state-of-the-art
MA Nauck, DR Quast, J Wefers, JJ Meier - Molecular metabolism, 2021 - Elsevier
Background GLP-1 receptor agonists (GLP-1 RAs) with exenatide bid first approved to treat
type 2 diabetes in 2005 have been further developed to yield effective compounds …
type 2 diabetes in 2005 have been further developed to yield effective compounds …
Beyond the pancreas: contrasting cardiometabolic actions of GIP and GLP1
Glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide 1 (GLP1)
exhibit incretin activity, meaning that they potentiate glucose-dependent insulin secretion …
exhibit incretin activity, meaning that they potentiate glucose-dependent insulin secretion …
Cardiovascular and renal outcomes with efpeglenatide in type 2 diabetes
Background Four glucagon-like peptide-1 (GLP-1) receptor agonists that are structurally
similar to human GLP-1 have been shown to reduce the risk of adverse cardiovascular …
similar to human GLP-1 have been shown to reduce the risk of adverse cardiovascular …
Effects of tirzepatide versus insulin glargine on kidney outcomes in type 2 diabetes in the SURPASS-4 trial: post-hoc analysis of an open-label, randomised, phase 3 …
Background In the SURPASS-4 trial, the dual GIP and GLP-1 receptor agonist tirzepatide
reduced HbA 1c concentrations, bodyweight, and blood pressure more than titrated daily …
reduced HbA 1c concentrations, bodyweight, and blood pressure more than titrated daily …
Diabetic vascular diseases: molecular mechanisms and therapeutic strategies
Y Li, Y Liu, S Liu, M Gao, W Wang, K Chen… - Signal transduction and …, 2023 - nature.com
Vascular complications of diabetes pose a severe threat to human health. Prevention and
treatment protocols based on a single vascular complication are no longer suitable for the …
treatment protocols based on a single vascular complication are no longer suitable for the …
The rationale, design and baseline data of FLOW, a kidney outcomes trial with once-weekly semaglutide in people with type 2 diabetes and chronic kidney disease
Background Chronic kidney disease (CKD) is a common complication of type 2 diabetes
(T2D). Glucagon-like peptide-1 receptor agonists (GLP-1RAs) improve glycaemic control …
(T2D). Glucagon-like peptide-1 receptor agonists (GLP-1RAs) improve glycaemic control …
Cardiovascular, mortality, and kidney outcomes with GLP-1 receptor agonists in patients with type 2 diabetes: a systematic review and meta-analysis of cardiovascular …
Summary Background Glucagon-like peptide-1 (GLP-1) receptor agonists differ in their
structure and duration of action and have been studied in trials of varying sizes and with …
structure and duration of action and have been studied in trials of varying sizes and with …
Dulaglutide and cardiovascular outcomes in type 2 diabetes (REWIND): a double-blind, randomised placebo-controlled trial
HC Gerstein, HM Colhoun, GR Dagenais, R Diaz… - The Lancet, 2019 - thelancet.com
Background Three different glucagon-like peptide-1 (GLP-1) receptor agonists reduce
cardiovascular outcomes in people with type 2 diabetes at high cardiovascular risk with high …
cardiovascular outcomes in people with type 2 diabetes at high cardiovascular risk with high …
KDIGO 2020 clinical practice guideline for diabetes management in chronic kidney disease
IH de Boer, ML Caramori, JCN Chan… - Kidney …, 2020 - kidney-international.org
This is an opportune time to publish the first KDIGO 2020 Clinical Practice Guideline for
Diabetes Management in Chronic Kidney Disease (CKD). Worldwide, the estimated number …
Diabetes Management in Chronic Kidney Disease (CKD). Worldwide, the estimated number …